Mutated HER2 genes are rare (prevalence: 2–4%) in non‐small‐cell lung cancer (NSCLC) patients, and are enriched in patients who are females, non‐smokers and younger, and in adenocarcinoma patients [2, 3]. Here, ERBB2 is linked to adenocarcinoma.